Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded down 8.4% on Thursday . The stock traded as low as $4.68 and last traded at $4.68. 1,064,198 shares traded hands during mid-day trading, a decline of 12% from the average session volume of 1,214,366 shares. The stock had previously closed at $5.11.
Several analysts have weighed in on the stock. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, January 23rd. ValuEngine lowered shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, February 14th. Finally, Barclays started coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, December 20th. They issued an “equal weight” rating and a $6.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $8.29.
The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.23. The firm has a market cap of $461.92, a P/E ratio of -5.90 and a beta of 2.71.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.06). BioCryst Pharmaceuticals had a negative net margin of 261.18% and a negative return on equity of 106.53%. The firm had revenue of $3.89 million during the quarter, compared to the consensus estimate of $6.07 million. During the same period in the prior year, the business earned ($0.06) earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was down 56.7% compared to the same quarter last year. equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.79 EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in BCRX. SG Americas Securities LLC increased its holdings in BioCryst Pharmaceuticals by 98.6% in the 3rd quarter. SG Americas Securities LLC now owns 26,990 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 13,402 shares during the period. Wells Fargo & Company MN grew its holdings in shares of BioCryst Pharmaceuticals by 50.7% during the 3rd quarter. Wells Fargo & Company MN now owns 96,671 shares of the biotechnology company’s stock valued at $507,000 after purchasing an additional 32,530 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 320,078 shares of the biotechnology company’s stock valued at $1,678,000 after purchasing an additional 12,267 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in shares of BioCryst Pharmaceuticals by 35.5% during the 3rd quarter. Allianz Asset Management GmbH now owns 159,364 shares of the biotechnology company’s stock valued at $835,000 after purchasing an additional 41,727 shares during the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at approximately $2,358,000. 91.54% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/biocryst-pharmaceuticals-bcrx-shares-down-8-4.html.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.